Finance And Administration Director
CurrentDaiichi Sankyo in the 2nd biggest Japanese pharmaceutical company. Its key drug in the UK market is in the cardiovascular space, and its product pipeline includes a further cardiovascular drug entry and multiple Oncology products including a joint venture arrangement with Astra Zeneca. DSUK is currently ranked as the 2nd fastest growing company in the UK Pharma industry.Business partner to UK affiliate in building the back office infrastructure and decision making insight and performance management to support a 700% growth in the net revenue of the business.Key Deliverables• Full financial and statutory accountability for the UK affiliate, significantly improving the controls and processes to manage the exponential top-line growth.• Drive enhanced performance management and decision support capability in the company.• Deliver a new business partnering capability in the function to support the growth of the current portfolio, through innovative new-to-industry Tenders with the NHSE, as well as the business cases for the product pipeline, including creating the joint venture construct with Astra Zeneca.• Create an enhanced Supply chain and customer service structure to support the supply of the UK patient.